• KOL
    • Myocardial Infarction
    • Braunwald Braunwald
    • Braunwald Braunwald: Influence Statistics

      Braunwald Braunwald

      Braunwald Braunwald

      Show email address

      From the TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, and the Department of Medicine, Harvard Medical School, Boston. | TIMI Study ...

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile

      Braunwald Braunwald:Expert Impact

      Concepts for whichBraunwald Braunwaldhas direct influence:Myocardial infarction,Heart failure,Atrial fibrillation,Acute myocardial infarction,Unstable angina,Acute coronary,Thrombolytic therapy,Acute coronary syndrome.

      Braunwald Braunwald:KOL impact

      Concepts related to the work of other authors for whichfor which Braunwald Braunwald has influence:Heart failure,Myocardial infarction,Atrial fibrillation,Bariatric surgery,Cardiovascular disease,Coronary artery,Blood pressure.

      KOL Resume for Braunwald Braunwald

      Year
      2022

      From the TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, and the Department of Medicine, Harvard Medical School, Boston.

      TIMI Study GroupBrigham and Women's Hospital Boston MA.

      Thrombolysis in Myocardial Infarction Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, Massachusetts.

      Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA

      2021

      TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA (E.B.).

      Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

      Harvard Medical School, Boston, MA (E.S.L., E.B., D.A.M., R.P.G., E.M.A., B.M.S., E.A.B., S.D.W., K.I., J.G., M.S.S., M.O.D., D.L.B., C.P.C.).

      2020

      TIMI Study Group, Division of Cardiovascular Medicine, Harvard Medical School, Boston, MA, USA.

      Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts

      From the Department of Medicine, Brigham and Women's Hospital, and Harvard Medical School - both in Boston.

      Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

      2019

      TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA (E.B., M.S.S.).

      Brigham and Womens Hospital, Boston, United States of America

      Division of Research, Kaiser Permanente Northern California, Oakland, CA, USA

      Sign-in to see all concepts, it's free!
      Sample of concepts for which Braunwald Braunwald is among the top experts in the world.
      Concept World rank
      tri nstemi #1
      atorvastatin 80 pravastatin #1
      sigmar 73 percent #1
      nhlbi thrombolysis #1
      vasodilator tolerance #1
      study drug consent #1
      early peak #1
      death icva #1
      ventricular contraction patients #1
      95 enoxaparin strategy #1
      total pep events #1
      8040 women #1
      infusion 60 minutes #1
      heart angiocardiography #1
      ventrikel #1
      digoxin digoxin administration #1
      digitoxin development #1
      95 sapt #1
      muscle forearm #1
      enox unfractionated heparin #1
      enoxaparin combination therapy #1
      ≥100× #1
      28 study #1
      ticagrelor cardiovascular death #1
      stemi cva #1
      cineradiograms #1
      nrmi stemi #1
      intact dogs dogs #1
      extracttimi 25 trial #1
      12 months hstnt #1
      costs drug costs #1
      non‐st‐elevation #1
      pg higher risk #1
      major bleeding efficacy #1
      hscrp 1 3 #1
      st15m #1
      infarct size thickness #1
      prevention events #1
      timi timi study #1
      norepinephrine tyramine #1
      crcl trs #1
      ejection fraction study #1
      tnktissue plasminogen activator #1
      acs 30 #1
      nrmi patients stemi #1
      48 analysis #1
      increase myocardial #1
      cardiovascular stress patients #1
      stent implantation clopidogrel #1
      thickness ventricular wall #1
      Sign-in to see all concepts, it's free!

      Prominent publications by Braunwald Braunwald

      KOL-Index: 24806

      BACKGROUND: Patients with diabetes mellitus (DM) are at high risk for recurrent cardiovascular events after acute coronary syndromes, in part because of increased platelet reactivity. The Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38) showed an overall reduction in ischemic events with more intensive antiplatelet therapy with prasugrel than with clopidogrel but with more ...

      Known for Dm Prasugrel | Myocardial Infarction | Platelet Inhibition | Therapeutic Outcomes | Diabetes Mellitus
      KOL-Index: 22196

      OBJECTIVES: We evaluated the relative contributions of the loading and maintenance doses of prasugrel on events in a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.

      BACKGROUND: Prasugrel is superior to clopidogrel in preventing ischemic events in patients with an acute coronary syndrome who are undergoing percutaneous coronary intervention, but it is associated with an ...

      Known for Platelet Inhibition | Myocardial Infarction | Therapeutic Outcomes | Assess Improvement | Coronary Syndrome
      KOL-Index: 21729

      BACKGROUND: Four new oral anticoagulants compare favourably with warfarin for stroke prevention in patients with atrial fibrillation; however, the balance between efficacy and safety in subgroups needs better definition. We aimed to assess the relative benefit of new oral anticoagulants in key subgroups, and the effects on important secondary outcomes.

      METHODS: We searched Medline from Jan 1, 2009, to Nov 19, 2013, limiting searches to phase 3, randomised trials of patients with atrial ...

      Known for New Oral Anticoagulants | Atrial Fibrillation | Randomised Trials | Systemic Embolic Events | Intracranial Haemorrhage
      KOL-Index: 21253

      OBJECTIVES: We evaluated the efficacy and safety of prasugrel and clopidogrel in the setting of a glycoprotein (GP) IIb/IIIa inhibitor.

      BACKGROUND: Prasugrel reduced cardiovascular events as compared with clopidogrel in TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38) but with increased bleeding.

      METHODS: Researchers in the TRITON-TIMI 38 randomized 13,608 subjects with acute ...

      Known for Myocardial Infarction | Platelet Inhibition | Glycoprotein Iib | Prasugrel Clopidogrel | Acute Coronary Syndromes
      KOL-Index: 21141

      BACKGROUND: Statin therapy has been shown to reduce major vascular events and vascular mortality in a wide range of individuals, but there is uncertainty about its efficacy and safety among older people. We undertook a meta-analysis of data from all large statin trials to compare the effects of statin therapy at different ages.

      METHODS: In this meta-analysis, randomised trials of statin therapy were eligible if they aimed to recruit at least 1000 participants with a scheduled treatment ...

      Known for Statin Therapy | Older People | Major Vascular Events | 75 Years | Age Patients
      KOL-Index: 21042

      CONTEXT: Enoxaparin or the combination of glycoprotein IIb/IIIa inhibitor tirofiban with unfractionated heparin independently have shown superior efficacy over unfractionated heparin alone in patients with non-ST-elevation acute coronary syndromes (ACS). It is not clear if combining enoxaparin with glycoprotein IIb/IIIa inhibitors is as safe or as effective as the current standard combination of unfractionated heparin with glycoprotein IIb/IIIa inhibitors.

      OBJECTIVE: To assess efficacy ...

      Known for Unfractionated Heparin | Enoxaparin Patients | Glycoprotein Iib | Acute Coronary | Myocardial Infarction
      KOL-Index: 20719

      OBJECTIVES: The purpose of this study was to assess the value of recombinant desulfatohirudin (hirudin) as adjunctive therapy to thrombolysis in acute myocardial infarction.

      BACKGROUND: Failure to achieve initial reperfusion and reocclusion of the infarct-related artery remain major limitations of thrombolytic therapy despite aggressive regimens of heparin and aspirin. Hirudin, a direct thrombin inhibitor, has been shown in experimental models to enhance thrombolysis and reduce ...

      Known for Myocardial Infarction | Plasminogen Activator | Recombinant Desulfatohirudin | Heparin Hirudin | Thrombolysis Reocclusion
      KOL-Index: 20653

      CONTEXT: The benefit of clopidogrel pretreatment before percutaneous coronary intervention (PCI) remains debated and its use has not been universally adopted.

      OBJECTIVE: To determine if clopidogrel pretreatment before PCI in patients with recent ST-segment elevation myocardial infarction (STEMI) is superior to clopidogrel treatment initiated at the time of PCI in preventing major adverse cardiovascular events.

      DESIGN, SETTING, AND PARTICIPANTS: The PCI-Clopidogrel as Adjunctive ...

      Known for Clopidogrel Pretreatment | Pci Patients | Myocardial Infarction | Cardiovascular Death | Stemi Balloon
      KOL-Index: 20533

      BACKGROUND: Clopidogrel and prasugrel are subject to efflux via P-glycoprotein (encoded by ABCB1, also known as MDR1). ABCB1 polymorphisms, particularly 3435C→T, may affect drug transport and efficacy. We aimed to assess the effect of this polymorphism by itself and alongside variants in CYP2C19 on cardiovascular outcomes in patients treated with clopidogrel or prasugrel in TRITON-TIMI 38. We also assessed the effect of genotype on the pharmacodynamic and pharmacokinetic properties of ...

      Known for Genetic Variants | Clopidogrel Prasugrel | Cardiovascular Outcomes | Abcb1 Cyp2c19 | Primary Endpoint
      KOL-Index: 19828

      BACKGROUND: Peripheral artery disease (PAD) is associated with heightened ischemic and bleeding risk in patients with prior myocardial infarction (MI).

      OBJECTIVES: This study evaluated the efficacy and safety of ticagrelor on major cardiovascular (CV) events and major adverse limb events in patients with PAD and a prior MI.

      METHODS: PEGASUS-TIMI 54 (Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of ...

      Known for Myocardial Infarction | Pad Patients | Ischemic Events | Peripheral Artery Disease | Placebo Background
      KOL-Index: 19483

      BACKGROUND: Although therapy with aspirin or aspirin plus a thienopyridine reduces the incidence of long-term adverse cardiovascular events among patients with acute coronary syndrome (ACS), there remains a significant residual risk of cardiovascular death, recurrent myocardial infarction (MI), and stroke. In a phase 2 trial (ClinicalTrials.gov NCT00402597) in which the addition of the factor Xa inhibitor rivaroxaban was compared with placebo, among ACS patients receiving either aspirin ...

      Known for Acute Coronary Syndrome | Myocardial Infarction | Standard Therapy | Timi 51 | Patients Acs
      KOL-Index: 19446

      BACKGROUND: Intracoronary stenting can improve procedural success and reduce restenosis compared with balloon angioplasty in patients with acute coronary syndromes, but can also increase the rate of thrombotic complications including stent thrombosis. The TRITON-TIMI 38 trial has shown that prasugrel-a novel, potent thienopyridine-can reduce ischaemic events compared with standard clopidogrel therapy. We assessed the rate, outcomes, and prevention of ischaemic events in patients treated ...

      Known for Stent Thrombosis | Ischaemic Events | Timi 38 | Patients Prasugrel | Acute Coronary Syndromes
      KOL-Index: 19266

      BACKGROUND: Although improved epicardial blood flow (as assessed with either TIMI flow grades or TIMI frame count) has been related to reduced mortality after administration of thrombolytic drugs, the relationship of myocardial perfusion (as assessed on the coronary arteriogram) to mortality has not been examined.

      METHODS AND RESULTS: A new, simple angiographic method, the TIMI myocardial perfusion (TMP) grade, was used to assess the filling and clearance of contrast in the myocardium in ...

      Known for Tmp Grade | Timi Myocardial | Thrombolytic Drugs | Epicardial Artery | 3 Flow
      KOL-Index: 19033

      IMPORTANCE: Small studies suggest that low-dose dopamine or low-dose nesiritide may enhance decongestion and preserve renal function in patients with acute heart failure and renal dysfunction; however, neither strategy has been rigorously tested.

      OBJECTIVE: To test the 2 independent hypotheses that, compared with placebo, addition of low-dose dopamine (2 μg/kg/min) or low-dose nesiritide (0.005 μg/kg/min without bolus) to diuretic therapy will enhance decongestion and preserve renal ...

      Known for Dose Dopamine | Acute Heart Failure | Renal Dysfunction | Difference 95 | Natriuretic Peptide

      Key People For Myocardial Infarction

      Top KOLs in the world
      #1
      Braunwald Braunwald
      myocardial infarction heart failure atrial fibrillation
      #2
      Robert M Califf
      myocardial infarction thrombolytic therapy heart failure
      #3
      Frans J J Van de Werf
      myocardial infarction acute coronary thrombolytic therapy
      #4
      Eric J Topol
      myocardial infarction thrombolytic therapy coronary angioplasty
      #5
      Christian Wilhelm Hamm
      myocardial infarction aortic valve acute coronary syndromes
      #6
      Harlan M Krumholz
      heart failure united states acute myocardial infarction

      From the TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, and the Department of Medicine, Harvard Medical School, Boston. | TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, and D

    Download on the App StoreGet it on Google Play

    Copyright © 2023 Key Opinion Leaders, LLC.